Comparative Analysis Of Four Beta Blocker Trials Presented At The American College Of Cardiology 58TH Annual Scientific Session
March 29, 2009
Data From GencaroTM Phase 3 Best Trial At The American College Of Cardiology 58th Annual Scientific Session
March 29, 2009
Two Gencaro™ Posters to be Presented at the American College of Cardiology 58th Annual Scientific Session
March 19, 2009
ARCA biopharma Appoints Kathryn Falberg as Chief Financial Officer and Chief Operating Officer
January 27, 2009
January 12, 2009
ARCA biopharma to Present at 27th Annual JPMorgan Healthcare Conference
January 8, 2009
October 2, 2008
September 25, 2008
September 23, 2008
Arca Discovery, Inc. announces data demonstrating potential for Bucindolol as targeted therapy in heart failure, atrial fibrillation, and ventricular arrhythmia.
November 6th, 2007
Arca Discovery, Inc. completes $18 million equity financing to advance targeted cardiovascular therapies and submit lead product for approval this year.
June 8th, 2007
Arca Discovery, Inc. Announces Appointment of J. William Freytag, PH.D. to its Board of Directors
March 9th, 2007
Arca Discovery and LabCorp® partner to commercialize companion diagnostic for first cardiovascular personalized medicine
February 13th, 2007
ARCA Discovery, Inc. Names Richard B. Brewer President and Chief Executive Officer
November 6, 2006
ARCA Discovery, Inc. Names Thomas Keuer Executive Vice President of Pharmaceutical Operations
October 30, 2006
ARCA Discovery, Inc. Announces Publication of the Genetic Basis for Enhanced Response to Bucindolol
July 17, 2006
ARCA Discovery, Inc. Names Dr. Ann Lenich Hards Executive Vice President Regulatory Affairs
July 10, 2006
ARCA Discovery, Inc. Raises $15 Million In Series A Financing
March 2, 2006
